Protease-Activated Receptors (PAR)

ML-161 is an inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50 = 0.26 μM for the inhibition of platelet P-selectin expression on human platelets).

I-287 is an orally active and selective protease-activated receptor 2 (PAR2) inhibitor that functions as a negative allosteric modulator, specifically targeting Gαq and Gα12/13 signaling pathways and their downstream effectors. By disrupting PAR2-mediated signaling, I-287 effectively reduces inflammation in preclinical models, including Complete Freund's Adjuvant (CFA)-induced inflammation in mice.

PAR-2-IN-1 is a selective inhibitor of protease-activated receptor-2 (PAR2), targeting the PAR2 signaling pathway. This compound exhibits significant anti-inflammatory and anticancer properties, making it a valuable tool in research. Its capabilities provide insights into the role of PAR2 in various biological processes and diseases, facilitating the investigation of therapeutic interventions in inflammation and cancer.

CBK289001 is an inhibitor of tartrate-resistant acid phosphatase (TRAP/ACP5). It effectively inhibits TRAP 5bMV, TRAP 5bOX, and TRAP 5aOX with IC50 values of 125 µM, 4.21 µM, and 14.2 µM, respectively. This compound is useful for studying the role of TRAP in various biological processes and may aid in the development of therapeutic strategies targeting TRAP-related pathways.

APC 366 TFA is an irreversible inhibitor of mast cell tryptase, a key enzyme involved in allergic responses. This reagent is instrumental in research focused on allergic diseases and related inflammatory processes. Its ability to effectively inhibit tryptase makes it a valuable tool for studying the mechanisms underlying mast cell activation and associated pathologies.

PAR4 Antagonist 4 is a selective inhibitor of protease-activated receptor 4 (PAR4), demonstrating potent antiplatelet activity with an IC50 of 14.2 nM. This compound exhibits enhanced metabolic stability in human liver microsomes, with a half-life (T1/2) of 42.5 minutes. PAR4 Antagonist 4 is suitable for research applications focused on hemostasis, cardiovascular disorders, and the modulation of platelet activation pathways.

PAR4 antagonist 3 is a selective inhibitor of protease-activated receptor 4 (PAR4). This compound demonstrates significant antiplatelet activity, with an IC50 value of 26.1 nM, making it a valuable tool for studies related to thrombosis and platelet function. Additionally, PAR4 antagonist 3 shows improved metabolic stability in human liver microsomes, with a half-life of 97.6 minutes, enhancing its potential for in vivo applications.

ML161 analog 1 is a selective allosteric inhibitor targeting Proteinase-Activated Receptor 1 (PAR1) with an IC50 of 1.68 μM. This compound modulates PAR1 activity, making it a valuable tool for studying its role in various biological processes and disease mechanisms. Its application in research may provide insights into therapeutic strategies involving PAR1.

TRAP-6-IN-1 is a dual inhibitor targeting collagen and TRAP-6, with IC50 values of 17.12 µM and 11.88 µM, respectively. This compound effectively inhibits agonist-induced platelet aggregation in a non-competitive manner, making it a valuable tool for research into platelet function and coagulation disorders. Its dual action may provide insights into therapeutic strategies for cardiovascular diseases associated with platelet hyperactivity.

PAR-2-IN-2 is a selective inhibitor of protease-activated receptor 2 (PAR-2), exhibiting an IC50 of 10.79 μM against the PAR-2 peptide SLIGKV, while demonstrating a significantly higher IC50 of over 200 μM for Trypsin. This compound is valuable for studying PAR-2 signaling pathways and exploring its role in inflammatory responses and pain modulation. PAR-2-IN-2 serves as a critical tool for researchers investigating therapeutic targets in conditions associated with PAR-2 activation.